コロンビア特別区における多発性骨髄腫の臨床試験
コロンビア特別区内の拠点で、多発性骨髄腫に関する10件の研究が参加者を募集しています。
コロンビア特別区内の都市
公式研究テキスト（英語）
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Washington D.C.
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07391657A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
- Lombardi Comprehensive Cancer Center, Washington D.C.
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/21更新 · NCT04661137A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Georgetown University Medical Center, Washington D.C.
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06615479Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- MedStar Washington Hospital Center MedStar Georgetown Cancer Institute, Washington D.C.
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/11更新 · NCT07555938Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Sibley Memorial Hospital, Washington D.C.
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04566328Mosaic Trial for Stem Cell Transplant Recipients
- Georgetown University School of Medicine, Washington D.C.
被験者募集中
18歳以上 · 全性別 · 2026/08/03更新 · NCT06960993Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Sibley Memorial Hospital, Washington D.C.
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/04更新 · NCT05243797Cancer Experience Registry (CER) for Cancer Patients and Caregivers
- Cancer Support Community Research & Training Institute, Washington D.C.
被験者募集中観察研究健康なボランティア歓迎
18歳以上 · 全性別 · 2026/04/23更新 · NCT02333604A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Washington D.C.
被験者募集中第3相
18歳以上 · 全性別 · 2026/04/22更新 · NCT06679101A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/03/24更新 · NCT04988555ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。